Guggenheim Starts Coverage on Stoke Therapeutics with Buy Rating and $60 Target

Guggenheim initiates coverage on Stoke Therapeutics, highlighting Zorevunersen’s potential as a disease-modifying treatment for Dravet syndrome and projecting $2.5B peak sales.